VANCOUVER, WASHINGTON (November 14, 2017) - Newly published research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development...
Credit: Journal of Hepatology Amsterdam, November 14, 2017 - Nonalcoholic fatty liver disease (NAFLD) is one of the more common chronic liver diseases worldwide. It...
Metastatic or castrate-resistant prostate cancer can spread to the bone in certain patients. While several new treatments are available, they can have a difficult time...
Credit: University of Delaware/ Wenbo Fan Doctors have many weapons in the fight against cancer, but choosing the right one can be a challenge. Soon...
PITTSBURGH, Nov. 13, 2017 - When low-income adults were newly covered by Medicaid under the Affordable Care Act (ACA), they were more likely to quit...
The Telomere and Telomerase Group at the Spanish National Cancer Research Centre (CNIO) has shown that it is possible to block the growth of human...
The University of California, Davis, and the Leibniz Institute for Photonic Technologies in Jena, Germany, have entered an agreement of cooperation to establish the Jena-Davis...
Scientists have discovered the 'genetic signatures' of the most common form of bladder cancer - and it could open up the possibility of better-targeted treatment,...
PHILADELPHIA -- (Nov. 13, 2017) -- Researchers from The Wistar Institute discovered a novel form of crosstalk among tumor cells and other cell types in...
Contrary to what was previously believed, the immune system's cancer-killing T cells are more effective in a tumour's anoxic environment when they have access to...
Credit: ETH Zurich T-cells are one of the immune system's major weapons. They detect the body's cells infected with a virus and trigger their ablation,...
Scientists have created mini biological models of human primary liver cancers, known as organoids, in the lab for the first time. In a paper published...
NOVEMBER 13, 2017, NEW YORK - Ludwig Cancer Research has released the scope of its participation at this year's Annual Meeting and Education Day of...
LUGANO, Switzerland, 13 November, 2017 - ESMO, the leading professional organisation for medical oncology, is pleased to announce the publication of the ESMO Precision Medicine...
(Pharmamar) PharmaMar (MSE:PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing´s sarcoma at the Connective Tissue Oncology Society´s (CTOS) International...
